Interactions between Tafasitamab and Ticlid

The ticlopidine in Ticlid has a major potential interaction with Bleeding Disorder.

The use of ticlopidine is contraindicated in patients with hemostatic disorders such as vascular defect or coagulation dysfunction or active pathological bleeding such as peptic ulcer disease or intracranial hemorrhage. Ticlopidine induces an irreversible inhibition of platelet aggregation resulting in a prolongation of bleeding time.

The ticlopidine in Ticlid has a major potential interaction with Coagulation Defects and Disorders.

The use of ticlopidine is contraindicated in patients with hemostatic disorders such as vascular defect or coagulation dysfunction or active pathological bleeding such as peptic ulcer disease or intracranial hemorrhage. Ticlopidine induces an irreversible inhibition of platelet aggregation resulting in a prolongation of bleeding time.

The ticlopidine in Ticlid has a moderate potential interaction with High Cholesterol.

Ticlopidine can induce increases in serum cholesterol and triglycerides. Serum total cholesterol levels have increased 8% to 10% in some patients within 1 month of initiation of ticlopidine therapy and have persisted at those levels. Clinical monitoring of lipid profiles is recommended during ticlopidine therapy in patients at risk for hyperlipidemia-associated adverse events.

The ticlopidine in Ticlid has a major potential interaction with Liver Disease.

The use of ticlopidine is contraindicated in patients with severe hepatic impairment. Ticlopidine is extensively metabolized to inactive forms by the liver. Therapy with ticlopidine should be administered cautiously in patients with mild to moderate hepatic impairment and dosage modifications should be considered. Clinical monitoring of hepatic function and bleeding activity is recommended.

Tafasitamab has a moderate potential interaction with Liver Disease.

The effect of moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN and any aspartate aminotransferase), on tafasitamab pharmacokinetics is unknown.

The ticlopidine in Ticlid has a major potential interaction with Neutropenia.

The use of ticlopidine is contraindicated in patients with hematopoietic disorders such as neutropenia and/or thrombocytopenia or a past history of thrombotic thrombocytopenic purpura (TTP) or aplastic anemia. Ticlopidine can cause life-threatening hematological adverse reactions, including neutropenia/agranulocytosis, TTP and aplastic anemia. Clinical monitoring of hematopoietic function is required for all patients receiving ticlopidine, since severe hematopoietic disorders may develop suddenly, usually within the first 3 weeks to 3 months of therapy. CBCs (including differential and platelet count) should be performed prior to initiation of ticlopidine and every 2 weeks through the first 3 months or as often as necessary.

Tafasitamab has a moderate potential interaction with Renal Dysfunction.

The effect of severe renal impairment to end-stage renal disease (ClCr less than 30 mL/min) on tafasitamab pharmacokinetics is unknown.

The ticlopidine in Ticlid has a moderate potential interaction with Renal Dysfunction.

Ticlopidine is primarily eliminated by the kidney, and there is limited experience in patients with renal impairment. Elevated serum concentration of ticlopidine and prolonged half-live have been noted in patients with mild and moderate renal impairment. Prolonged bleeding times have been reported in patients with moderate renal impairment. Therapy with ticlopidine should be administered cautiously in patients with compromised renal function and dosage modifications may be necessary.

The ticlopidine in Ticlid has a major potential interaction with Thrombocytopathy.

The use of ticlopidine is contraindicated in patients with hemostatic disorders such as vascular defect or coagulation dysfunction or active pathological bleeding such as peptic ulcer disease or intracranial hemorrhage. Ticlopidine induces an irreversible inhibition of platelet aggregation resulting in a prolongation of bleeding time.

The ticlopidine in Ticlid has a major potential interaction with Thrombocytopenia.

The use of ticlopidine is contraindicated in patients with hematopoietic disorders such as neutropenia and/or thrombocytopenia or a past history of thrombotic thrombocytopenic purpura (TTP) or aplastic anemia. Ticlopidine can cause life-threatening hematological adverse reactions, including neutropenia/agranulocytosis, TTP and aplastic anemia. Clinical monitoring of hematopoietic function is required for all patients receiving ticlopidine, since severe hematopoietic disorders may develop suddenly, usually within the first 3 weeks to 3 months of therapy. CBCs (including differential and platelet count) should be performed prior to initiation of ticlopidine and every 2 weeks through the first 3 months or as often as necessary.